<abstract xmlns="http://www.w3.org/1999/xhtml"><italic>Staphylococcus aureus</italic> is currently a significant multidrug-resistant bacterium, causing severe healthcare-associated and community-acquired infections worldwide. The current antibiotic regimen against this pathogen is becoming ineffective due to resistance, in addition, they disrupt the normal microbiota. It highlights the urgent need for a pathogen-specific drug with high antibacterial efficacy against <italic>S. aureus</italic>. α-Viniferin, a bioactive phytochemical compound, has been reported to have excellent anti-<italic>Staphylococcus</italic> efficacy as a topical agent. However, so far, there were no clinical trials that have been conducted to elucidate its efficacy. The present study aimed to investigate the antibacterial efficacy of α-viniferin against <italic>S. aureus</italic> in a ten-day clinical trial. Based on the results, α-viniferin showed 50% minimum inhibitory concentrations (MIC50 values) of 7.8 μg/ml in culture broth medium. α-Viniferin was administered in the nares three times a day for ten days using a sterile cotton swab stick. Nasal swab specimens were collected before (0 days) and after finishing the trial (10th day), and then analyzed. In the culture and RT-PCR-based analysis, <italic>S. ureus</italic> was reduced significantly: 0.01. In addition, 16S ribosomal RNA-based amplicon sequencing analysis showed that <italic>S. aureus</italic> reduced from 51.03% to 23.99% at the genus level. RNA-seq analysis was also done to gain insights into molecular mechanisms of α-viniferin against <italic>S. aureus</italic>, which revealed that some gene groups were reduced in 5-fold FC cutoff at two times MIC conditions. The study results demonstrate α-viniferin as a potential <italic>S. aureus</italic>-specific drug candidate.</abstract>

Staphylococcus aureus is currently a significant multidrug-resistant bacterium, causing severe healthcare-associated and community-acquired infections worldwide. The current antibiotic regimen against this pathogen is becoming ineffective due to resistance, in addition, they disrupt the normal microbiota. It highlights the urgent need for a pathogen-specific drug with high antibacterial efficacy against S. aureus. α-Viniferin, a bioactive phytochemical compound, has been reported to have excellent anti-Staphylococcus efficacy as a topical agent. However, so far, there were no clinical trials that have been conducted to elucidate its efficacy. The present study aimed to investigate the antibacterial efficacy of α-viniferin against S. aureus in a ten-day clinical trial. Based on the results, α-viniferin showed 50% minimum inhibitory concentrations (MIC50 values) of 7.8 μg/ml in culture broth medium. α-Viniferin was administered in the nares three times a day for ten days using a sterile cotton swab stick. Nasal swab specimens were collected before (0 days) and after finishing the trial (10th day), and then analyzed. In the culture and RT-PCR-based analysis, S. ureus was reduced significantly: 0.01. In addition, 16S ribosomal RNA-based amplicon sequencing analysis showed that S. aureus reduced from 51.03% to 23.99% at the genus level. RNA-seq analysis was also done to gain insights into molecular mechanisms of α-viniferin against S. aureus, which revealed that some gene groups were reduced in 5-fold FC cutoff at two times MIC conditions. The study results demonstrate α-viniferin as a potential S. aureus-specific drug candidate.

A Clinical Trial to Evaluate the Efficacy of α-Viniferin in <italic>Staphylococcus aureus</italic> – Specific Decolonization without Depleting the Normal Microbiota of Nares

Polish Journal of Microbiology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

A Clinical Trial to Evaluate the Efficacy of α-Viniferin in  – Specific Decolonization without Depleting the Normal Microbiota of Nares

Staphylococcus aureus is currently a significant multidrug-resistant bacterium, causing severe healthcare-associated and community-acquired infections...

A Clinical Trial to Evaluate the Efficacy of α-Viniferin in Staphylococcus aureus – Specific Decolonization without Depleting the Normal Microbiota of Nares

Article Category: original-paper

Publié en ligne: 19 mars 2021

Pages: 117 - 130

Reçu: 28 déc. 2020

Accepté: 08 févr. 2021

DOI: https://doi.org/10.33073/pjm-2021-011

Mots clés
α-viniferin, clinical trial, MRSA, PCR, 16S rRNA amplicon sequencing analysis

© 2021 Md Abdur Rahim et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

A Clinical Trial to Evaluate the Efficacy of α-Viniferin in Staphylococcus aureus – Specific Decolonization without Depleting the Normal Microbiota of Nares

Article Category: original-paper

Publié en ligne: 19 mars 2021

Pages: 117 - 130

Reçu: 28 déc. 2020

Accepté: 08 févr. 2021

DOI: https://doi.org/10.33073/pjm-2021-011

Mots clésα-viniferin, clinical trial, MRSA, PCR, 16S rRNA amplicon sequencing analysis

© 2021 Md Abdur Rahim et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mots clés
α-viniferin, clinical trial, MRSA, PCR, 16S rRNA amplicon sequencing analysis